Efficacy of Intracavernosal as add-on Therapy to Sildenafil 100 mg on Demand Compared to Sildenafil 100 mg on Demand for the Treatment of Erectile Dysfunction (ED) Not Sufficiently Responsive to Standard Therapy With Phosphodiesterase Type 5 Inhibitors — MENOX

Erectile Dysfunction Clinical Trial

Official title:
Efficacy of Intracavernosal (Xeomin®) 100U as add-on Therapy to Sildenafil 100 mg on Demand Compared to Sildenafil 100 mg on Demand for the Treatment of Erectile Dysfunction (ED) Not Sufficiently Responsive to Standard Therapy With Phosphodiesterase Type 5 Inhibitors

Status Active, not recruiting

Clinical Trial Summary

The primary objective of this study is to investigate the efficacy of intracavernosal (Xeomin®) (100U) as add-on therapy to sildenafil 100 mg on demand in men with ED and insufficient response to standard therapy with 100 mg sildenafil on demand during the 4-week open-label run-in phase. The secondary objectives are to further describe the efficacy and safety of (Xeomin®) 100U IC as add-on therapy to sildenafil 100 mg on demand: 1. to further assess efficacy using. - i) a log diary five-item questionnaire completed after each sexual attempt (Sexual Encounter Profile); - ii) a self-reporting measure that scores erection hardness on a 4 point scale completed after each sexual attempt; - iii) The Global Assessment Question. 2. to assess effect persistence at month 6 and month 9. 3. to assess safety of (Xeomin®) 100U IC in combination with sildenafil 100 mg on demand.

Clinical Trial Description

This randomized, double-blind, placebo-controlled study will be conducted in 9 centers, study participants will be adult men with ED and insufficient response to standard therapy with 100 mg sildenafil on demand during the 4-week open label run-in-phase, follow-up in the study will be 10±2 months. This is a standard procedure to use placebo as control in studies assessing the efficacy of pharmacological treatment of ED. Furthermore the placebo group provides a benchmark for an objective analysis of safety and tolerability findings. The open-label run-in phase assures that only subjects who are true non-responders i.e. with insufficient response to standard therapy with 100 mg sildenafil prn during the 4-week open-label run-in phase are randomized and participate in the double-blind treatment phase. Participants distributed between groups at a ratio of 1:1. ;

Study Design

Related Conditions & MeSH terms

Erectile Dysfunction

Clinical Trial Details

NCT number	NCT05196308
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 18, 2022
Completion date	March 28, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05366504` - LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment	Phase 2/Phase 3
Recruiting	`NCT02745808` - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes	Phase 1
Recruiting	`NCT02573805` - the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males	N/A
Withdrawn	`NCT01967251` - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction	Phase 2
Withdrawn	`NCT02579148` - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes	Phase 1
Recruiting	`NCT02225548` - Sagene 2014 - Parkinson's Disease and Erectile Dysfunction	Phase 4
Completed	`NCT02587988` - Trial to Evaluate the Efficacy and Safety of HCP1302	Phase 3
Completed	`NCT02945462` - Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)	Phase 1
Completed	`NCT01937871` - A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)	Phase 3
Completed	`NCT01698684` - Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction	Phase 4
Not yet recruiting	`NCT01321489` - A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies	Phase 3
Terminated	`NCT01262833` - Pudendal Assessment in Erectile Dysfunction	N/A
Completed	`NCT01230541` - Effect of Udenafil on Spermatogenesis	Phase 1
Completed	`NCT02226237` - Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy	N/A
Completed	`NCT01037244` - Treatment of Erectile Dysfunction I	Phase 3
Completed	`NCT01037218` - Treatment of Erectile Dysfunction II	Phase 3
Recruiting	`NCT00313898` - Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males	Phase 4
Completed	`NCT00667979` - Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse	Phase 4
Completed	`NCT00421083` - Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury	Phase 3
Completed	`NCT00663728` - Assessment of Duration of Erection With Vardenafil 10 mg	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.